Abstract:Stroke is one of the main causes of death, neurological dysfunctions or disability in elderly. Neuroprotective drugs have been proposed to improve long-term recovery after stroke, but failed to reach clinical effectiveness. Hence, recent studies suggested that restorative therapies should combine neuroprotection and remyelination. Montelukast, an anti-asthmatic drug, was shown to exert neuroprotection in animal models of CNS injuries, but its ability to affect oligodendrocytes, restoring fiber connectivity, remains to be determined. In this study, we evaluated whether montelukast induces long-term repair by promoting fiber connectivity up to 8 weeks after middle cerebral artery occlusion (MCAo), using different experimental approaches such as in vivo diffusion magnetic resonance imaging (MRI), electrophysiological techniques, ex vivo diffusion tensor imaging (DTI)-based fiber tracking and immunohistochemistry. We found that, in parallel with a reduced evolution of ischemic lesion and atrophy, montelukast increased the DTI-derived axial diffusivity and number of myelin fibers, the density of myelin binding protein (MBP) and the number of GSTpi+ mature oligodendrocytes. Together with the rescue of MCAo-induced impairments of local field potentials in ischemic cortex, the data suggest that montelukast may improve fibers reorganization. Thus, to ascertain whether this effect involved changes of oligodendrocyte precursor cells (OPCs) activation and maturation, we used the reporter GPR17iCreERT2:CAG-eGreen florescent protein (GFP) mice that allowed us to trace the fate of OPCs throughout animal's life. Our results showed that montelukast enhanced the OPC recruitment and proliferation at acute phase, and increased their differentiation to mature oligodendrocytes at chronic phase after MCAo. Considering the crosstalk between OPCs and microglia has been widely reported in the context of demyelinating insults, we also assessed microglia activation. We observed that montelukast influenced the phenotype of microglial cells, increasing the number of M2 polarized microglia/macrophages, over the M1 phenotype, at acute phase after MCAo. In conclusion, we demonstrated that montelukast improves fiber re-organization and long-term functional recovery after brain ischemia, enhancing recruitment and maturation of OPCs. The present data suggest that montelukast, an already approved drug, could be "repositioned "as a protective drug in stroke acting also on fiber re-organization.

THE INDEPENDENT NEWSPAPER SERVING NOTRE DAME AND SAINT MARY ’ S Dornan says Clinton was guest of KGB

Montelukast as a successful treatment for eosinophilic cystitis in an asthmatic woman patient.

Montelukast modulates lung CysLT1 receptor expression and eosinophilic inflammation in asthmatic mice

Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction

Montelukast, a Leukotriene Receptor Antagonist, Modulates Lung CysLT1

Anti-Leukotrienes in the treatment of allergic conjunctivitis and comorbidities in children: An update

Montelukast, A Cysteinyl Leukotriene Receptor-1 Antagonist, Attenuates Chronic Brain Injury after Focal Cerebral Ischaemia in Mice and Rats

A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms

Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders

Montelukast prevents mice against carbon tetrachloride- and methionine-choline deficient diet-induced liver fibrosis: Reducing hepatic stellate cell activation and inflammation

Study on Cysteinyl Leukotriene Receptor Antagonist Depressing Acute Asthma Airway Inflammation

Montelukast: results and prospects for applications in pediatric practice

Lactobacillus strains differentially modulate cytokine production by hPBMC from pollen-allergic patients.

The contribution of the WNT pathway to the therapeutic effects of montelukast in experimental murine airway inflammation induced by ovalbumin and lipopolysaccharide

Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug

[Homozygote erythropoietic protoporphyria associated with porokeratosis].

SOI design for a high-performance IO interface

Suspected Adverse Drug Reactions Associated With Leukotriene Receptor Antagonists Versus First Line Asthma Medications: A National Registry-Pharmacology Approach

Revision reverse shoulder arthroplasty in failed shoulder arthroplasties for rotator cuff deficiency.

Cys-leukotrienes mediate lung dysfunction but not histopathologies in an IL-5/Eotaxin-2 double transgenic mouse model of severe asthma

Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients